Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a solid tumour cancer.
- People who are planning to start a specific chemotherapy regimen (listed below) within 3 days after being enrolled in the trial, either before or after surgery: weekly paclitaxel for 12 weeks; weekly paclitaxel for 12 weeks plus carboplatin; paclitaxel plus carboplatin every 3 weeks for 6 cycles; or docetaxel plus carboplatin every 3 weeks for 6 cycles. Certain additional medicines such as pembrolizumab, trastuzumab, pertuzumab, or bevacizumab may also be taken alongside these regimens.
- People aged 18 years or older.
- People who are willing to provide biological samples (such as blood or tissue) for research storage, with their consent.
- People who are able to complete health and wellbeing questionnaires written in English or Spanish.
- People who agree to complete health and wellbeing questionnaires at all scheduled times during the trial, and who complete the first questionnaire within 14 days before being enrolled.
- People who have been fully informed about the research nature of this study and have signed a consent form. If a person is unable to make their own decisions, a legally authorised representative may sign the consent form on their behalf.
Who may not be able to join:
- People who have a history of cancer that has spread to the skin or limbs.
- People who have previously received chemotherapy known to affect the nerves (such as taxanes, platinum-based drugs, vinca alkaloids, or bortezomib).
- People who already have nerve damage in their hands or feet (peripheral neuropathy) from any cause.
- People who have a history of certain conditions affecting blood flow in cold temperatures or circulation in the limbs, such as Raynaud's phenomenon, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, post-traumatic cold dystrophy, or peripheral arterial ischemia (confirm with trial site if unsure about these conditions).
- People who have any open wounds or ulcers on their arms or legs at the time of enrolment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Melissa K Accordino, SWOG - Columbia University
Phone: 210-614-8808
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of clinically meaningful chemotherapy induced peripheral neuropathy (CIPN) (binary outcome: yes vs. no)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.